Literature DB >> 23288750

Excellent results of revision TKA in Jehovah's Witness patients.

Steven F Harwin1, Kimona Issa, Qais Naziri, Robert Pivec, Aaron J Johnson, Michael A Mont.   

Abstract

Revision total knee arthroplasty (TKA) can be quite challenging in Jehovah's Witness patients because blood transfusion is often needed, however, these patients do not accept allogeneic or autologous blood due to religious convictions. We reported our clinical experiences with a special blood management protocol for Jehovah's Witnesses who underwent a revision TKA. There were 12 self-reported Jehovah's Witness patients (12 total knee arthroplasties) who had a mean age of 69 years (range: 55 to 79 years) and who underwent revision TKA between 1998 and 2009. All revision surgeries were due to aseptic component failure. Implant survivorship was 100% over a mean follow-up of 62 months (range: 24 to 120 months). The Knee Society objective and function scores improved to a mean of 83 and 82 points, respectively. The authors believe that the use of this blood management protocol was responsible for the excellent clinical outcomes. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23288750     DOI: 10.1055/s-0032-1324812

Source DB:  PubMed          Journal:  J Knee Surg        ISSN: 1538-8506            Impact factor:   2.757


  2 in total

1.  Tranexamic Acid in a Multimodal Blood Loss Prevention Protocol to Decrease Blood Loss in Revision Total Knee Arthroplasty: A Cohort Study.

Authors:  Miguel Ortega-Andreu; Gloria Talavera; Norma G Padilla-Eguiluz; Hanna Perez-Chrzanowska; Reyes Figueredo-Galve; Carlos E Rodriguez-Merchán; Enrique Gómez-Barrena
Journal:  Open Orthop J       Date:  2016-09-23

2.  Does tourniquet use decrease blood loss following primary total knee arthroplasty in Jehovah's Witness patients?

Authors:  Ali Levent; Özkan Köse; Philip Linke; Thorsten Gehrke; Mustafa Çıtak
Journal:  Jt Dis Relat Surg       Date:  2020
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.